| Ytd | -34.15% | |
| 1y | -37.54% |
| Open | 8.72 | Prev Close | 8.75 | Low | 8.71 | High | 9.02 | Mkt Cap | 309.41M |
| Vol | 73.14K | Avg Vol | 154.86K | EPS | -0.98 | P/E | N/A | Forward P/E | -1.23 |
| Beta | 0.88 | Short Ratio | 1.35 | Inst. Own | 82.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 11.72 | 200-d Avg | 11.85 | 1yr Est | 25.43 |
BNTC News
The BB-301 pivotal trial remains on track to begin in mid-2027 Discussions regarding an open-label,
Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report)'s share price crossed below its 50-day mo
Benitec Biopharma (BNTC) is technically in oversold territory now, so the heavy selling pressure mig
Benitec Biopharma (NASDAQ: BNTC - Get Free Report) is expected to announce its Q4 2026 results befor
Wedbush analyst Yun Zhong maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.26) per share which met the analyst
All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-u
AWM Investment Company Inc. acquired a new position in Benitec Biopharma Limited (NASDAQ: BNTC) in t
Top Wall Street analysts changed outlook on top names. See all rating changes on analyst ratings pag
Wedbush analyst Yun Zhong initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.24) per share which beat the analys
Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and
- Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-u
HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec”
-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-tre
Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) Director Suvretta Capital Management, L b
Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) Director Suvretta Capital Management, L p
The average of price targets set by Wall Street analysts indicates a potential upside of 83.9% in Be
Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) Director Suvretta Capital Management, L b
The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 87.5% upside in the st
Benitec Biopharma (BNTC) has become technically an oversold stock now, which implies exhaustion of t
– Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) re
In the past week or so, beneficial owners Carl Icahn and Mario Gabelli made some big bets in Monro I
Gainers Tango Therapeutics, Inc. (NASDAQ: TNGX) climbed 85.2% to $7.09 after gaining 11% on Tuesd
On Wednesday, 155 companies set new 52-week lows.
During Tuesday's trading, 188 companies set new 52-week lows.
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) surged 46.2% to $8.80. Minerva Neurosciences
On Monday, 413 companies reached new 52-week lows.
During Monday's session, 101 companies made new 52-week lows.
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 12
During Wednesday's trading, 517 companies set new 52-week lows.
On Monday, 429 stocks made new 52-week lows.
During Friday's session, 574 stocks hit new 52-week lows.
On Tuesday, 126 companies set new 52-week lows.
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 73.8% to $19.48 after the company announced
On Wednesday, 297 companies achieved new lows for the year.
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after th
Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after g
Wednesday's session saw 51 companies set new 52-week lows.
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday
On Thursday, 216 stocks hit new 52-week lows.
On Tuesday, 951 companies hit new 52-week lows.
During Monday's trading, 1214 companies set new 52-week lows.
On Wednesday, 216 stocks hit new 52-week lows.
During Thursday, 351 stocks hit new 52-week lows.